Sartorius Stedim Biotech SA

The global cell isolation and cell separation market is projected to grow from USD 6.97 billion in 2026 to USD 13.51 billion by 2032, a compound annual growth rate of 11.39%, according to a new report from ResearchAndMarkets.com. The report profiles major players including Thermo Fisher Scientific, Bio-Rad Laboratories, Beckman Coulter, and Sartorius AG. Growth is driven by demand for high-purity, viable cells for single-cell sequencing, flow cytometry, and adoptive cell therapy, with the industry shifting from manual, open protocols toward automated, closed, digitally controlled systems. Artificial intelligence is cited as improving image-based cell recognition, flow cytometry gating, and quality control, while North America leads regional demand and Asia-Pacific expands through biotechnology and genomics investment in China, India, Japan, South Korea, and Australia.

Sartorius AG reported group sales revenue increased by 7.7% on an operational basis in constant currencies for the first half of 2026. The Bioprocess Solutions division grew 8.3% operationally, driven by consumables, while Lab Products and Services rose 5.3%. Underlying EBITDA margin improved to 30.3%, and free cash flow jumped more than 70% to 208 million euros. Net debt to underlying EBITDA improved to 3.51 times from 3.55 times at year-end 2025, and underlying net profit increased 2% to 172 million euros. The company noted tariff-related customer compensations created a temporary headwind, and delayed orders from two major customers in advanced therapies impacted recurring revenue growth.

The global laboratory plasticware market is projected to grow from US$ 2.25 billion in 2024 to US$ 2.99 billion by 2034, at a compound annual growth rate of 4.72%, according to a new report from Zion Market Research. The market is driven by expanding life sciences research, drug discovery, and the shift from glass to durable, low-cost plastics. Low-density polyethylene (LDPE) leads the material segment with a 29% share, while diagnostic centers dominate end-users with a 37% share. Asia Pacific holds the largest regional share, fueled by manufacturing capabilities and healthcare investments in China and India. Key players include Thermo Fisher Scientific, Eppendorf, Corning, and Sartorius.

The global bioprocess digital twin market is projected to grow from USD 0.89 billion in 2025 to USD 6.47 billion by 2035, at a compound annual growth rate of 19.6%, according to a new report by Healthcare Foresights. The market is expected to reach USD 1.08 billion in 2026. Growth is driven by increasing adoption of virtual process replicas to reduce batch failures, accelerate technology transfer, and enable real-time optimization, supported by rising biopharma R&D spending and a growing pipeline of complex biologics and cell and gene therapies. North America currently dominates the market due to its large biopharmaceutical manufacturing base and stringent regulatory emphasis on digital validation, while the Asia-Pacific region is expected to grow fastest, fueled by expanding biomanufacturing capabilities in China, India, and South Korea. In a recent development, Sartorius launched an advanced bioprocess digital twin platform in June 2025 that incorporates AI-based predictive control and real-time multivariate analysis, reducing process development times by up to 40% for monoclonal antibodies and viral vectors.

The global cell therapy human raw materials market is projected to grow from USD 3.62 billion in 2025 to USD 18.94 billion by 2035, at a compound annual growth rate of 16.3% during the forecast period from 2026 to 2035, according to a report by Healthcare Foresights. The market was valued at approximately USD 3.62 billion in 2025 and is expected to reach USD 4.21 billion in 2026. Key players include Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), Sartorius AG, and others. Growth is driven by increasing cell therapy clinical trials and approvals, rising prevalence of cancer and chronic diseases, and advancements in GMP-compliant, xeno-free, and serum-free formulations. North America dominated the market in 2025, while the Asia Pacific region is expected to show the fastest growth.

The global stem cell culture media market is projected to grow from approximately USD 765 million in 2025 to around USD 2714 million by 2035, at a compound annual growth rate of about 13.5 percent during the forecast period from 2026 to 2035, according to a new report by Healthcare Foresights. The market was valued at roughly USD 765 million in 2025 and is expected to reach USD 868 million in 2026. Growth is driven by the shift toward serum-free, xeno-free, and chemically defined media, as well as increasing integration of stem cell technologies in drug discovery and cell and gene therapy programs. North America held the highest market share in 2025, while the Asia Pacific region is expected to register the highest growth rate. Key players include Thermo Fisher Scientific, Merck KGaA, Lonza Group, and Sartorius AG.